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Aim: This work is intended to develop and evaluate a biopolymeric poly(L-γ-glutamyl-
glutamine) (PGG)–docetaxel (DTX) conjugate that can spontaneously self-assemble in aqueous 
solutions to become nanoparticles.
Methods: DTX was covalently attached to hydrophilic PGG by direct esterification, and the con-
jugate was characterized by proton nuclear magnetic resonance spectroscopy, molecular weight 
gel permeation chromatography, solubility, size distribution and morphology, and hemolysis. 
Conjugated DTX was found to have 2000 times improved water solubility compared with free 
DTX. Dynamic light scattering, transmission electron microscopy, and atomic force microscopy 
revealed the particle size, distribution and morphology of the PGG–DTX conjugate. In addition, 
the conjugate was further tested for in vitro cytotoxicity and in vivo antitumor efficacy on the 
human non-small cell lung cancer cell line NCI-H460.
Results: Conjugated DTX was found to have 2000 times improved water solubility compared 
with free DTX. The conjugate formed nanoparticles with an average diameter of 30 nm in spheri-
cal shape and unimodal particle size distribution. The conjugate exhibited about 2% hemolysis 
at 10 mg/mL, compared with 56% for Tween 80® at 0.4 mg/mL, and 33% for Cremophor EL® 
at 10 mg/mL. In addition, the conjugate was further tested for in vitro cytotoxicity and in vivo 
antitumor efficacy on the human non-small cell lung cancer cell line NCI-H460. As expected, 
conjugated DTX exhibited lower cytotoxicity compared to that of free DTX, in concentration-
dependent manner. However, PGG–DTX showed better antitumor activity in NCI-H460 lung 
cancer-bearing mice with minimal weight loss compared to that of free DTX.
Conclusion: The PGG–DTX conjugate may be considered as an attractive and promising 
polymeric DTX conjugate for non-small cell lung cancer treatment.
Keywords: polymer drug delivery, nanotechnology, nanotherapeutics, drug delivery, nano-
medicine, pharmaceutics
Introduction
Docetaxel (DTX) is a hydrophobic semisynthetic analog of paclitaxel.1 DTX is approved by the 
US Food and Drug Administration (FDA) to be used alone or with other drugs as second-line 
treatment for patients with advanced/metastatic non-small cell lung cancer.2 It is also approved 
by the FDA for use in combination with cisplatin and 5-fluorouracil for the induction treatment 
of patients with locally advanced squamous cell carcinoma of the head and neck and for the 
treatment of patients with advanced gastric adenocarcinoma. In 2004, the FDA approved DTX 
for use in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of 
women with operable node-positive breast cancer, and for use in combination with prednisone 
for the treatment of metastatic, androgen-independent (hormone-refractory) prostate cancer.3 
In terms of toxicity, the main grade 3–4 toxicity of the current clinical DTX formulation, which 
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features nonionic surfactant Tween 80® and ethanol (50:50, v/v) 
as the excipients, were neutropenia and leukopenia.2,4–8   Currently, 
a number of strategies are being employed to develop novel, sur-
factant (Tween 80)-free formulations of DTX.9 These formulations 
include lecithin-in-water emulsions of DTX,10 DTX–liposomes,11,12 
DTX-loaded glycol chitosan nanoparticles,13 DTX-loaded 
micelles,14–16 DTX-loaded solid lipid nanoparticles,17 and DTX-
loaded poly(lactic acid)-poly(ethylene glycol) nanoparticles.18 In 
addition to the abovementioned approaches, DTX conjugation 
is another strategy to eliminate the side effects of Tween 80 and 
ethanol. Some examples of DTX conjugates include luteinizing 
hormone-releasing hormone receptor peptide,19 linoleic,20 methoxy 
polyethylene glycol,16 albumin protein,21 low molecular weight chi-
tosan,22 and N-(2-hydroxypropyl)-methacrylamide copolymers.23 
Similar to the non-conjugated formulations of DTX discussed 
above, the development of these DTX conjugates is also in the 
early stages. Only limited polymers are suitable as drug delivery 
vehicles because of the requirement for biocompatibility and 
biodegradability.24
Very recently, we reported the synthesis, pharmacokinetics, 
and efficacy of poly(L-g-glutamylglutamine-paclitaxel) 
conjugate (PGG-paclitaxel conjugate).25–27 The effectiveness 
of the PGG–paclitaxel (PTX) conjugate for treating cancer 
is likely to be a result of various factors including: (1) the 
increased water solubility of paclitaxel by conjugation to 
water-soluble polymer PGG, which could avoid the use of 
surfactants or excipients, and the PGG–PTX conjugate can 
be dissolved in saline or phosphate-buffered saline (PBS) for 
intravenous injection; (2) “enhanced permeability and reten-
tion” effects that were related to the preferential accumulation 
of PGG–PTX conjugate in hypervascular tumor tissue and 
low excretion from kidney filtration due to the high molecular 
weight of the conjugate; (3) self-assembling of PGG–PTX 
conjugate into nanoparticles of less than 50 nm, which 
might contribute to passive tumor targeting; (4) increased 
tumor accumulation of active paclitaxel might be due to the 
selective release of paclitaxel mediated by high local tumor 
carboxylesterases and/or tumor macrophages; (5) improved 
therapeutic index by exposure to the slow, prolonged release 
of paclitaxel from the conjugate. Encouraged with the results, 
we hypothesized that the PGG–drug conjugate could be used 
as a technological platform capable of improving the efficacy 
of anticancer drugs. However, since the physicochemical 
properties of each PGG–drug conjugate may be different, we 
are currently exploring one drug at a time with the platform of 
PGG-drug conjugate. Herein we report the synthesis, physical 
properties, hematological toxicity, in vitro cytotoxicity, and 
in vivo antitumor efficacy of the PGG–DTX conjugate.
Materials and methods
Materials
Poly(L-glutamic acid), sodium salt (Mw 20 kDa), dimethylfor-
mamide, sodium bicarbonate, and 4-di(methylamino) pyridine 
were purchased from Sigma-Aldrich Chemical Co, (St Louis, 
MO). N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide, 
L-glutamic acid di-tert-butyl ester hydrochloride, and 
trifluoroacetic acid were purchased from Novabiochem 
(La Jolla, CA). 1-Hydroxybenzotriazole was purchased 
from Spectrum (Gardena, CA). DTX was purchased from 
NuBlocks (Vista, CA). All the chemicals and reagents were 
used as received without further purification.
Mice and cell lines
Female BALB/c nude mice, 6–8 weeks of age, were from 
Vital River Laboratories, Inc (Beijing, China). The NCI-
H460 cell line was obtained from the American Type Culture 
Collection (Manassas, VA) and grown in RPMI 1640 medium   
(Sigma-Aldrich) supplemented with 10% fetal bovine serum, 
100 U/mL of penicillin (Invitrogen, Carlsbad, CA), and 
100 µg/mL of streptomycin (Invitrogen).
Synthesis of PGG–DTX conjugate
Synthesis of the PGG–DTX conjugate was carried out fol-
lowing our previously published procedure25 with the modifi-
cation of replacing paclitaxel with DTX. Briefly, PGG–DTX 
was synthesized in a two-step process. First, PGG was pre-
pared from poly(L-glutamic acid), sodium salt, Mw 20 kDa) 
with the addition of L-glutamic acid di-tert-butyl ester 
hydrochloride in the presence of 1-hydroxybenzotriazole 
and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide in 
anhydrous dimethylformamide solvent. Subsequently, the 
t-butyl ester protecting group from PGG–di-tert-butyl ester 
intermediate was deprotected with trifluoroacetic acid under 
anhydrous conditions, and PGG was isolated after dialysis 
against water and   lyophilization. Subsequently, PGG–DTX 
was synthesized by coupling DTX with PGG in the pres-
ence of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
coupling agent and a trace of 4-di(methylamino) pyridine 
catalyst in anhydrous dimethylformamide solvent. The reac-
tion mixture was stirred continuously for 24 hours at room 
temperature. The reaction was determined as completed by 
thin layer chromatography (spot of the DTX disappeared in 
ethyl acetate). Then, the solution was poured into an excess 
amount of 0.2 M HCl, and the precipitate was collected. 
PGG–DTX was re-dissolved in 0.3 M NaHCO3 and dialyzed 
against water overnight (15 hours). Finally, the PGG–DTX 
conjugate was obtained after lyophilization.
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Characterization
1h-NMR spectroscopy and gel permeation 
chromatography measurement
1H-NMR spectra were obtained on an NMR spectrometer 
(Varian, Palo Alto, CA) using CDCl3 for DTX and D2O 
for PGG–DTX. Chemical shifts were reported in ppm. Gel 
permeation chromatography measurements were performed 
using a gel permeation chromatography–multi-angle light-
scattering detector. This was operated with a ChemStation 
program with Agilent 1200 analytical series and ASTRA 
V program with Wyatt Technology Company Dawn Heleos 
light-scattering detector and refractive index detector. The col-
umn was Shodex OHpak, SB 804HQ (Phenomenex, Torrance, 
CA) with a guard column, SB-G 605038. The mobile phase 
was phosphate buffer solution (50 mM phosphate, 50 mM 
sodium chloride, 200 ppm sodium azide, pH 6.5) and 45% 
CH3OH (high-performance liquid chromatography grade) 
by volume to volume. The injection volume was 100 µL and 
the elution was isocratic at a flow rate of 0.7 mL/minute over 
30 minutes with additional ultraviolet detection at 228 nm.
Determination of DTX content and solubility  
of the PGG–DTX conjugate
The conjugate was dissolved in distilled water, and its 
  ultraviolet–visible absorbance at 228 nm was measured.22 DTX 
content of the conjugate was determined based on a standard 
curve generated with a known concentration of DTX in metha-
nol solution. The solubility of the conjugate was measured by 
gravimetric analysis. A saturated solution of PGG–DTX was 
prepared with excess conjugate. The   solutions were stirred for 
5 hours at room temperature and then filtered through a 0.45 
µm PTFE syringe filter and lyophilized   (FreeZone Benchtop 
and Console Freeze Dry System,   Labconco, Kansas City, MO). 
After 48 hours, the dry powder was weighed and solubility was 
calculated as mg/mL.
Dynamic light-scattering (DLS) measurements
The particle size of the polymer conjugate solution was 
determined by DLS using a ZETASIZER Nano-ZS (Malvern 
  Instruments Inc, UK) equipped with He–Ne laser (4 mW, 
633 nm) light source and 90° angle scattered-light collec-
tion configuration. Polymer conjugate solution (2.0 mg/mL) 
was prepared in saline and the samples were equilibrated for 
5 minutes at 25°C before the measurements. Each sample was 
measured with 10 runs and 10 seconds duration before each run, 
and measurements were repeated three times. All the measure-
ments were done in triplicate, and average particle sizes were 
presented as the average diameter with standard deviation.
Transmission electron microscopy (TEM) and atomic 
force microscopy (AFM)
The morphology of PGG–DTX nanoparticles was observed 
using two techniques, (1) TEM and (2) AFM, to visualize 
the interface of the polymer at nanoscale. The TEM study 
was carried out using a TEM H-7000 (Hitachi, Tokyo, Japan) 
electron microscope operating at an accelerating voltage of 
75 kV . Negative staining was performed as follows: (1) a drop 
of sample solution was placed onto a copper grid coated with 
carbon, (2) the sample drop was tapped with a filter paper to 
remove surface water and air-dried for 5 minutes followed 
by the application of 0.01% phosphotungstic acid to deposit 
the micelles on the grid, and (3) the samples were air-dried 
before observation. The AFM studies were performed using 
a NanoScope III a MultiMode AFM (Digital Instruments/
Veeco Metrology Group, Santa Barbara, CA). One drop of 
the nanoparticle dispersion (0.05 mg/mL) was placed on the 
surface of fresh cover slip and air-dried at room temperature. 
The AFM measurements were operated in tapping mode.
hemolysis of the PGG–DTX 
nanoparticles
Hemolysis study was carried out according to the published 
procedure.28 Briefly, freshly collected rat blood was washed 
three times with PBS solution (pH 7.4) by centrifugation at 
1000 rpm for 5 minutes. The red blood cell suspension was 
diluted with saline to obtain a 2% suspension (v/v). Various 
concentrations of PGG-DTX, Tween 80 (Wei’er Chem, Nan-
jing, China), Cremophor EL® (Sigma-Aldrich), and saline 
samples in phosphate buffer were added into the RBC suspen-
sion. After incubation at 37°C for 1 hour, samples were centri-
fuged at 3000 rpm for 10 minutes to remove non-lysed RBC. 
The supernatants were collected and analyzed for hemoglobin 
content by spectrophotometric detection at 416 nm. Analysis 
of each sample was performed in triplicate. The data are pre-
sented as the mean with the standard deviation of the triplicate 
experiments after they were normalized with the data of the 
saline hemolysis. The results of the PGG–DTX hemolysis were 
compared with those of Tween 80 and Cremophor EL.
In vitro cytotoxicity assay
The cytotoxicity of PGG–DTX nanoparticles and free DTX 
against the human non-small cell lung cancer NCI-H460 cell 
line was evaluated using the (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
(MTS) method.25 Briefly, 100 µL of cell suspension in culture 
medium at a concentration of 3 × 104 cells/mL was seeded in 
each well of a 96-well plate, and incubated at 37°C in a humidi-
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fied atmosphere with 5% CO2. After overnight incubation, serial 
dilutions of PGG–DTX were added to the plate (100 µL/well). 
After further incubation for up to 72 hours, the cells were stained 
with MTS reagent (Promega). The absorbance at 490 nm was 
measured with a microplate reader (Thermo Multiskan MK3; 
Thermo Scientific, Waltham, MA). Survival was calculated 
as the absorbance in wells of treated cells and normalized 
to controls, and the concentration of drug that inhibited cell 
survival by 50% (IC50) was calculated by GraphPad Prism (v 
5; GraphPad Software, Inc, San Diego, CA).
Evaluation of antitumor activity in human 
tumor xenograft models
Tumor fragments (3 × 3 × 3 mm) of H460 cell were implanted 
subcutaneously in 6–8 week-old female nu/nu nude mice 
(Vital River, Beijing, China). Tumor diameters were mea-
sured two or three times per week using a sliding caliper. 
The tumor volume (TV) was calculated according to the 
formula TV = (L × W2)/2, where L and W were the length of 
the major and minor diameters, respectively. The drug treat-
ment was started when the tumors reached a size of 100 mm3. 
The tumor-bearing mice were randomly divided into six 
groups, with six mice to each group (n = 6). PGG–DTX was 
administered intravenously via tail-vein injection at doses of 
20 mg/kg, 40 mg/kg, 60 mg/kg, and 80 mg/kg, to four sepa-
rate groups of tumor-bearing mice three times within a 3-day 
interval. DTX at the maximum tolerated dose of 5 mg/kg and 
PBS solution were administered using the same injection 
method to one positive control group and one negative control 
group, respectively, of tumor-bearing mice.
Statistical analysis
The statistical significance of the data was evaluated by stu-
dent’s t test, and P , 0.05 was considered significant.
Results and discussion
The rationale of utilizing a macromolecular polymer–drug 
conjugate to improve the therapeutic indices of a small molecu-
lar anticancer drug is based on the concept of the combined 
effects of “enhanced permeability and retention.” These effects 
are attributed to disrupted vasculature, insufficient lymphatic 
drainage in the tumor tissue, and prolonged circulation time of a 
polymer-conjugated anticancer drug. By avoiding kidney filtra-
tion, such conjugates can passively accumulate in the targeted 
tumors.29,30 Recently, a number of polymer–anticancer drug 
conjugates were tested in clinical trials.31 The polymers included 
N-(2-hydroxypropyl)methacrylamide, poly(L-glutamate), and 
poly(ethylene glycol); the drugs conjugated were doxorubicin, 
paclitaxel, palatinate, and camptothecin. The poly(L-glutamic 
acid)–paclitaxel   conjugate (CT-2103) is considered the most 
advanced   polymer–paclitaxel conjugate to date32 and has been 
investigated in multiple Phase III clinical trials. However, CT-2103 
is not yet approved by the FDA for cancer treatment.33–35
1h-NMR spectra, molecular weight,  
and solubility of polymers
DTX was covalently attached to PGG through a direct esteri-
fication that is known to be hydrolyzed under physiological 
conditions. Conjugation between PGG and DTX was carried 
out using a similar procedure to that previously described by 
our laboratory for the synthesis of the PGG–paclitaxel conju-
gate.25 The conjugate was characterized by 1H-NMR, showing 
corresponding peaks to both PGG and DTX conjugated (Fig-
ure 1B and 1D, respectively).  DTX free and conjugated were 
identified and confirmed by proton chemical shifts at 7.0–8.0 
ppm for its aromatic protons (Figure 1C and 1D, respectively). 
The resonance at 4.0–4.5 ppm was assigned to the methylene 
protons of the PGG backbone (Figure 1B and D).
The molecular weights of the obtained polymers, as well as 
the polydispersity indices, were calculated by gel permeation 
chromatography with multi-angle light-scattering detection. The 
average molecular weight of PGG and PGG–DTX was about 
40 kDa and 90 kDa, respectively, with low polydispersity index 
(Table 1). The weight percentage of DTX in the PGG–DTX 
conjugate was determined to be ∼38 weight percent by mea-
suring ultraviolet absorption at a wavelength of 228 nm.25 The 
solubility of the PGG–DTX conjugate was .15 mg/mL of DTX 
equivalent, compared to that of free DTX which was reported to 
be approximately 6–7 µg/mL. Thus, the increase in solubility of 
conjugated DTX was approximately 2000-fold. This improved 
water solubility enabled the PGG–DTX conjugate to be dis-
solved in saline or PBS for in vitro and in vivo experiments 
without using Tween 80, ethanol, or other surfactants.
DLS and TEM morphology
The nanoparticle size and size distribution were measured by 
DLS. As depicted in Figure 2, the mean size of PGG–DTX 
nanoparticle dispersion was about 30 nm. The conjugate exhib-
ited unimodal particle size distribution with a low polydisper-
sity index of 0.225, which indicated that the dispersion was 
homogeneous. The average particle size and distribution of the 
PGG–DTX conjugate were confirmed by TEM and AFM that 
were used to directly visualize the size and morphology of the 
PGG–DTX conjugate in the dry state (Figures 2 and 3), show-
ing the nanoparticles were spherical with diameters around 
20–30 nm. The particle size of the PGG–DTX conjugate was 
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Figure 1 (A) The chemical structure of the PGG–DTX conjugate. 1h-NMR spectra of PGG polymer-length chain (B), free docetaxel (C) in CDCl3 in D2O and PGG–DTX 
nanoparticles (D).
Abbreviations: PGG, poly(L-γ-glutamyl-glutamine); DTX, docetaxel.
Table 1 Physical characteristics of the PGG–DTX conjugate
Conjugate DTX feeding  
ratio (%)
DTX  
content (%)
Zeta  
potential
Size  
(nm)
Polydispersity Molecular weight
Mw Mn Mw/Mn
PGG N/A N/A N/A N/A N/A 39.5 33.2 1.19
PGG–DTX 35% 38.2 -21.3 28.3 0.225 89.3 59.7 1.50
Abbreviations: PGG, poly(L-γ-glutamyl-glutamine); DTX, docetaxel; Mw, weight average molecular weight; Mn, number average molecular weight.
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Figure 2 Characterization of the PGG–DTX nanoparticles. The particle size and polydispersity of the PGG–DTX conjugate obtained from (A) dynamic light scattering, and 
(B) transmission electron microscopy.
Abbreviations: PGG, poly(L-γ-glutamyl-glutamine); DTX, docetaxel; Mw, weight average molecular weight; Mn, number average molecular weight.
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consistent with the particle size of the PGG–paclitaxel con-
jugate, which was previously reported.36,37 Zeta potential or 
particle surface charge is an important parameter, indicating 
the stability of nanocarrier systems. A relatively high surface 
charge may provide a repelling force between the particles, thus 
they could be more stable in solution due to less aggregation.38 
Table 1 shows that the PGG–DTX conjugate had high negative 
zeta potentials of –21.3 mV due to the presence of two ionized 
carboxylic acid groups in the PGG polymer backbone. It is 
reasonable to conclude that the charged particles may repel 
each other and prevent aggregation or precipitation.
hemolysis
To determine whether PGG–DTX induces membrane damage, 
a hemolysis study was conducted using procedures described 
in the literature.28 Our previous study showed that the backbone 
PGG carrier inherited good biocompatibility.25 In this study, PGG-
DTX showed no hemolytic activity even at high concentrations of   
10 mg/mL compared with those of the surfactant Tween 80, which 
caused significant red blood cell damage at low concentrations 
of 0.2–0.5 mg/mL to 1.0–2.0 mg/mL (Figure 4).  Cremophor EL 
did not induce substantial hemolysis until reaching its concentra-
tion of 4 mg/mL. Significantly, hemolytic activity of PGG–DTX 
was almost negligible even at high concentrations of 10 mg/mL. 
The results suggested that PGG–DTX would not induce anemic 
toxicity following systemic intravenous uses.
Cytotoxicity
The cytotoxicity of PGG–DTX was evaluated by the MTS 
method using NCI-H460 as the model human non-small lung 
cancer cell line, with formulated DTX as the control in Tween 
80:ethanol (1:1, v/v). As shown in Figure 5, the backbone 
carrier PGG did not cause significant cytotoxicity against 
the NCI-H460 cell line at experimental concentrations up to 
0.50 mg/mL. However, PGG–DTX and DTX were cytotoxic 
in a concentration-dependent manner. Experimental IC50 
values of PGG–DTX and DTX were found to be 88.1 ± 23.7 
and 4.1 ± 0.3 µg/L, respectively. As expected, the IC50 value 
of PGG–PTX was higher than the IC50 value of DTX, which 
indicated that DTX was still in a conjugated form and partially 
released into a free DTX form. At PGG–DTX concentrations 
of 0.01 mg/mL, the cell viability was reduced to 20%, while 
treatment with formulated free DTX reached this maximum 
cytotoxicity at a concentration of 0.0001 mg/mL (Figure 5).
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Figure 3 Tapping mode atomic force microscopy image of the poly(L-γ-glutamyl-
glutamine)–docetaxel conjugate.
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Figure 4 hemolysis of red blood cells after incubation with PGG–DTX, Tween 80®, 
and Cremophor EL®. 
Note:  Data  reported  as  means  of  three  independent  experiments  ±  standard 
error.
Abbreviations: PGG, poly(L-γ-glutamyl-glutamine); DTX, docetaxel.
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Figure  5  In  vitro  cytotoxicity  study  of  cells  treated  with  free  DTX  or  PGG–
DTX  for  72  hours  at  37°C,  evaluated  by  (3-(4,5-dimethylthiazol-2-yl)-5-(3-
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Abbreviations: PGG, poly(L-γ-glutamyl-glutamine); DTX, docetaxel.
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Figure 6 Antitumor efficacy in nude mice bearing NCI-H460 human non-small cell lung carcinoma tumors. (A) Mean tumor growth curves. (B) Body weight change.
Note: Data presented as means ± standard error.
Abbreviations: PBS, phosphate-buffered saline; PGG, poly(L-γ-glutamyl-glutamine); DTX, docetaxel.
PGG–DTX can be more potent and less 
toxic than DTX in a lung cancer model
Human non-small cell lung H460 carcinoma xenograft 
models were prepared to assess the effectiveness of the 
PGG–DTX conjugate in terms of inhibiting tumors in vivo. 
To determine the effect of the drugs on H460 tumor growth, 
PGG–DTX or DTX was given as three repeated intrave-
nous administrations as q3d × 3 after subcutaneous tumor 
  implantation. Antitumor activity was evaluated using the 
doses equal to or less than the maximum tolerated dose of 
each of the drugs. Tumor growth and body weight change of 
each group of mice were monitored and recorded.
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Figure 6 shows a plot of tumor volume and weight loss 
as a function of time in mice bearing NCI-H460 lung cancer. 
These mice were treated for 3 days with three doses of either 
PBS (negative control), PGG–DTX (20 mg/kg, 40 mg/kg, 
60 mg/kg, 80 mg/kg), or DTX (5 mg/kg, positive control). The 
PBS-treated group of mice showed a progressive increase in 
tumor growth for mean tumor volume up to day 37. The mice 
treated with DTX (5 mg/kg) showed significant tumor-growth 
inhibition (P , 0.05), relative to the PBS group (Figure 6A). 
However, DTX treatment caused an obvious decrease in body 
weight on day 15, which slowly recovered to its normal value 
(Figure 6B). In contrast, PGG–DTX treatments of 20 mg/kg, 
40 mg/kg, 60 mg/kg, and 80 mg/kg DTX equivalent caused 
minimal weight loss, within an acceptable range of 10%. 
Tumor-growth inhibition of PGG–PTX treatment (60 mg/kg 
DTX equivalent) was comparable to that of the treatment of 
free DTX (5 mg/kg), and inhibition of tumor growth of PGG–
DTX treatment (80 mg/kg DTX equivalent) outperformed the 
treatment of free DTX 5 mg/kg, in a statistically significant 
manner. Table 2 shows – after treatment with PGG–DTX and 
DTX – the tumor-growth inhibition rate and tumor volume 
on day 37, drug-related deaths up to day 37, and mean body 
weight on day 37 versus day 1, as a mean ± standard error of 
six mice/group. No drug-related deaths were observed. The 
tumor volume and tumor-inhibition rate of mice treated with 
20 mg/kg and 40 mg/kg DTX equivalent of PGG–DTX on 
day 37 were the same. However, as the dose of PGG–DTX 
increased from 40 mg/kg to 60 mg/kg, and to 80 mg/kg of 
DTX equivalent, the mean tumor volume decreased linearly, 
while tumor-inhibition rate increased linearly. These results 
clearly indicate the superiority of PGG–DTX over DTX, dem-
onstrating that the proper use of macromolecular carriers can 
increase the potency and the therapeutic indices of DTX.
Conclusion
In this work, biopolymer backbone PGG was successfully 
employed for the delivery of the hydrophobic antican-
cer drug DTX. PGG–DTX nanoparticles were achieved 
with high solubility, small size, uniform distribution, and 
  biocompability. The in vitro studies demonstrated that 
PGG–DTX was less cytotoxic compared with free DTX 
in a dose-dependent manner against NCI-H460 cells. The 
PGG–DTX conjugate showed in vivo antitumor efficacy to 
DTX at 80 mg/kg, and the toxicity in terms of body weight 
loss was markedly reduced compared to that of DTX. Taken 
together, our PGG–DTX conjugate can be considered as an 
alternative and promising biocompatible polymer to be used 
as a delivery system for cancer chemotherapy.
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